- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06146257
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximately 24 participants (up to 42 participants) may be enrolled in Phase 1a of the study.
The dose expansion part (Phase 1b) will be followed to understand the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Up to 24 participants (12 participants per dose level) may be enrolled in Phase 1b of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A standard 3+3 dose-escalation design will be applied to evaluate a set of several dose levels to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of GLB-001 in R/R AML or R/R HR-MDS patients who are eligible for DLT evaluation. The actual dose-escalation magnitude or dosing frequency may be adjusted based on the available PK and safety data in human.
After the MTD or MAD of GLB-001 is defined in Phase 1a, 1 or 2 dose levels will be selected for expansion per safety review committee (SRC) recommendation, approximately 12 patients will be enrolled per dose level. Recommended phase 2 dose (RP2D) will be selected based on the results of PK, PD, safety and efficacy in the dose escalation and expansion study.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Hongying Zhang, MD
- Phone Number: 619-859-4586
- Email: Hongying.Zhang@glubiotx.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Contact:
- Brian Ball, MD
- Phone Number: 626-218-4784
- Email: brball@coh.org
-
Irvine, California, United States, 92697
- Recruiting
- University of California Irvine
-
Contact:
- Deepa Jeyakumar, MD
- Phone Number: 714-456-2880
- Email: djeyakum@hs.uci.edu
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center Research Institute, Inc.
-
Contact:
- Jesus Gonzalez Lugo, MD
- Phone Number: 913-588-4138
- Email: jgonzalezlugo@kumc.edu
-
Merriam, Kansas, United States, 66204
- Recruiting
- Alliance for Multispecialty Research, LLC
-
Contact:
- Jaswinder Singh, MD
- Phone Number: 660-383-3197
- Email: jaswinder.singh@armllc.com
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Comprehensive Cancer Center
-
Contact:
- Eunice Wang, MD
- Phone Number: 716-845-3544
- Email: Eunice.Wang@RoswellPark.org
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Lewis Silverman, MD
- Phone Number: 212-241-5520
- Email: Lewis.silverman@mssm.edu
-
New York, New York, United States, 10021
- Recruiting
- Memorial Sloan Kettering Cancer Center-David H. Koch Center
-
Contact:
- Eytan Stein, MD
- Phone Number: 646-608-3749
- Email: SteinE@mskcc.org
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas M. D. Anderson Cancer Center
-
Contact:
- Gautman Borthakur, MD
- Phone Number: 713-563-1586
- Email: GBorthak@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants is ≥ 18 years of age at the time of signing the Informed Consent Form (ICF).
- Participants must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
- Participants are willing and able to adhere to the study visit schedule and other protocol requirements.
- Participants with histologically or cytologically confirmed AML including de novo AML or secondary AML transformed from MDS according to 2022 World Health Organization (WHO) criteria classification, or with histologically or cytologically confirmed HR-MDS.
- R/R AML and R/R HR-MDS who have failed or are ineligible for all available therapies which may provide clinical benefit.
Participants must have the following screening laboratory values:
- Total white blood cell count (WBC) < 25 x 10^9/L prior to the first dose of the study drug.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case AST and ALT can be ≤ 5.0 x ULN.
- Serum total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome, in which case serum total bilirubin < 3 x ULN.
- Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.
- International normalized ratio (INR) ≤ 1.5 x ULN and active partial thromboplastin time (aPTT) ≤ 1.5 x ULN.
- Life expectancy ≥ 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
- Female Participants of child-bearing potential must have a negative serum or urine pregnancy test at screening and at pre-dose on Cycle 1 Day 1 (C1D1).
Exclusion Criteria:
- Participants with acute promyelocytic leukemia (APML).
- Participants with known leukemic involvement in central nervous system (CNS).
- Receipt of anticancer medications/therapies within 5 half-lives or 28 days before the first administration of the study drug.
- Participants with unresolved clinically significant non-hematologic toxicities of ≥ Grade 2 AE from prior therapies with exception of residual alopecia.
- Participants with chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy.
- Participants with active malignancies other than AML or MDS.
- Participants who have undergone major surgery ≤ 4 weeks prior to the first dose of the study drug.
- Participants with immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection (bacterial and/or fungal), uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation.
- Participants with known chronic, active infection of hepatitis B virus (HBV), hepatitis C virus C (HCV), human immunodeficiency virus (HIV).
- Participants unable to swallow oral medications, or Participants with clinically significant diarrhea, vomiting or malabsorption felt limited absorption of orally administered medications.
- Participants with any other significant medical conditions, any other conditions, laboratory abnormality, or psychiatric illness which place the Participants at unacceptable risk if he/she were to participate in the study or that would hamper the Participants understanding of the study, or would prevent the Participant from complying with the study.
- Medications or supplements that are known to be strong and moderate inhibitors or inducers of CYP450 isozyme 3A4 (CYP3A4) and/or P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug.
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1a
Part 1a (Dose Escalation) of the study will enroll R/R AML and R/R HR-MDS participants and will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001 administered orally, and determine the maximum tolerated dose/maximum administered dose (MTD/MAD) in R/R AML or R/R HR-MDS patients who are eligible for dose limiting toxicity (DLT) evaluation.
|
Administered orally according to the assigned treatment schedule
Other Names:
|
Experimental: Dose Expansion of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1b
Part 1b (Dose Expansion) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML and R/R HR-MDS participants.
|
Administered orally according to the assigned treatment schedule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting Toxicity (DLT)
Time Frame: Up to 28 days after first dose of study treatment in Phase 1a
|
Dose-limiting toxicity is defined as the treatment emergent adverse events (TEAEs) meeting protocol specified DLT criteria and occurring within the DLT assessment period.
|
Up to 28 days after first dose of study treatment in Phase 1a
|
Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD)
Time Frame: Up to 2 years
|
Maximum tolerated dose is defined as the highest dose level at which no more than 1 of 6 DLT-evaluable participants experienced a DLT.
If MTD is not established at the end of dose escalation phase, the maximum safety dose will be defined as Maximum administered dose.
|
Up to 2 years
|
Incidence of Adverse Events (AEs)
Time Frame: Up to 2 years
|
Adverse Events will be graded according to the National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) version 5.0.
|
Up to 2 years
|
Recommended Phase 2 Dose (RP2D)
Time Frame: Up to 2 years
|
Recommended phase 2 dose based on the totality of data across dosing cohorts in the dose escalation and expansion phases of the study including PK, PD, safety and efficacy outcomes.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GLB-001 Pharmacokinetics-AUC0-last
Time Frame: Up to 2 years
|
Area under the concentration-time curve from zero to the last measurable concentration.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-AUC0-24
Time Frame: Up to 2 years
|
Area under the concentration-time curve from 0 to 24 hours.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-AUC0-∞
Time Frame: Up to 2 years
|
Area under the concentration-time curve from 0 to infinity.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-Cmax
Time Frame: Up to 2 years
|
Maximum plasma concentration.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-Tmax
Time Frame: Up to 2 years
|
The time to reach maximum concentration.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-T1/2
Time Frame: Up to 2 years
|
Terminal half-life.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-Vd/F
Time Frame: Up to 2 years
|
Apparent volume of distribution.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-LI
Time Frame: Up to 2 years
|
Linear index.
|
Up to 2 years
|
GLB-001 Pharmacokinetics-CL/F
Time Frame: Up to 2 years
|
Apparent clearance.
|
Up to 2 years
|
GLB-C183-A-2R (Isomer of GLB-001) Pharmacokinetics-AUC0-last
Time Frame: Up to 2 years
|
Area under the concentration-time curve from zero to the last measurable concentration.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-AUC0-24
Time Frame: Up to 2 years
|
Area under the concentration-time curve from 0 to 24 hours.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-AUC0-∞
Time Frame: Up to 2 years
|
Area under the concentration-time curve from 0 to infinity.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-Cmax
Time Frame: Up to 2 years
|
Maximum plasma concentration.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-Tmax
Time Frame: Up to 2 years
|
The time to reach maximum concentration.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-T1/2
Time Frame: Up to 2 years
|
Terminal half-life.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-Vd/F
Time Frame: Up to 2 years
|
Apparent volume of distribution.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-LI
Time Frame: Up to 2 years
|
Linear index.
|
Up to 2 years
|
GLB-C183-A-2R Pharmacokinetics-CL/F
Time Frame: Up to 2 years
|
Apparent clearance.
|
Up to 2 years
|
Complete Remission Without Minimal Residual Disease (CRMRD-) Rate in Participants with Acute Myeloid Leukemia (AML)
Time Frame: Up to 2 years
|
CRMRD- rate is defined as the percent of participants with minimal residual disease negative complete remission.
CRMRD- will be assessed by the 2022 European Leukemia Net Response Criteria (2022 ELN) for AML .
|
Up to 2 years
|
Complete Remission (CR) Rate in Participants with AML
Time Frame: Up to 2 years
|
CR rate is defined as the percent of participants whose best response is CR.
CR will be assessed by 2022 ELN for AML.
|
Up to 2 years
|
CR with Incomplete Hematologic Recovery (CRi) Rate in Participants with AML
Time Frame: Up to 2 years
|
CRi rate is defined as the percent of participants whose best response is CRi.
CRi will be assessed by 2022 ELN for AML.
|
Up to 2 years
|
CR with Partial Hematological Recovery (CRh) Rate in Participants with AML
Time Frame: Up to 2 years
|
CRh rate is defined as the percent of participants whose best response is CRh.
CRh will be assessed by 2022 ELN for AML.
|
Up to 2 years
|
Morphologic Leukemia-free State (MLFS) Rate in Participants with AML
Time Frame: Up to 2 years
|
MLFS rate is defined as the percent of participants with the best response of morphologic leukemia-free state.
MLFS will be assessed by 2022 ELN for AML.
|
Up to 2 years
|
Partial Remission (PR) Rate in Participants with AML
Time Frame: Up to 2 years
|
PR rate is defined as the percent of participants whose best response is PR.
PR will be assessed by 2022 ELN for AML.
|
Up to 2 years
|
Duration of Remission or Response (DOR) in Participants with AML
Time Frame: Up to 2 years
|
For participants with best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS, DOR is measured from the time when criteria (2022 ELN for AML) for the best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented assessment.
|
Up to 2 years
|
Time to Remission or Response (TOR) in Participants with AML
Time Frame: Up to 2 years
|
Time to onset of first remission or response is defined as the time interval from the date of first dose and the earliest date any remission or response [any CRs (including CR, CRh and CRi) or PR] is observed.
|
Up to 2 years
|
Stable Disease (SD) Rate in Participants with AML
Time Frame: Up to 2 years
|
SD rate is defined as the percent of participants with the best response of stable disease.
SD will be assessed by 2022 ELN for AML.
|
Up to 2 years
|
CR Rate in Participants with Higher Risk Myelodysplastic Syndromes (HR-MDS)
Time Frame: Up to 2 years
|
CR rate is defined as the percent of participants whose best response is CR.
CR will be assessed by 2006 Modified International Working Group (IWG) MDS response criteria.
|
Up to 2 years
|
PR Rate in Participants with HR-MDS
Time Frame: Up to 2 years
|
PR rate is defined as the percent of participants whose best response is PR.
PR will be assessed by 2006 Modified IWG MDS response criteria.
|
Up to 2 years
|
SD Rate in Participants with HR-MDS
Time Frame: Up to 2 years
|
SD rate is defined as the percent of participants with the best response of stable disease.
SD will be assessed by 2006 Modified IWG MDS response criteria.
|
Up to 2 years
|
DOR in Participants with HR-MDS
Time Frame: Up to 2 years
|
For participants with best response of any of CR, marrow CR, or PR, DOR is measured from the time when criteria (2006 Modified IWG MDS response criteria) for the best response of any of CR, marrow CR, or PR are first met (whichever is first recorded) until the first date at which relapse or progressive disease is objectively documented assessment.
|
Up to 2 years
|
TOR in Participants with HR-MDS
Time Frame: Up to 2 years
|
Time to onset of first remission or response is defined as the time interval from the date of first dose of GLB-001 and the earliest date any remission or response [any CRs (including CR, marrow CR or PR)] is observed.
|
Up to 2 years
|
Progression-free Survival (PFS) in Participants with AML or HR-MDS
Time Frame: Up to 2 years
|
PFS is defined as the time from the first dose of GLB-001 to the first occurrence of relapse or progression or death from any cause.
|
Up to 2 years
|
Overall Survival (OS) in Participants with AML or HR-MDS
Time Frame: Up to 2 years
|
OS is defined as the time from the first dose of GLB-001 to death due to any cause.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gang Lu, Ph.D., GluBio Therapeutics Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLB-001-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
Clinical Trials on GLB-001
-
Hangzhou GluBio Pharmaceutical Co., Ltd.RecruitingNon-Hodgkin LymphomaChina
-
University of PittsburghUnited States Department of DefenseCompletedMetabolic Syndrome | PrediabetesUnited States
-
Lovoria WilliamsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
University of PittsburghCompletedQuality of Life | Obesity | Physical Activity | Diet Modification | Cardiovascular Risk Factor | Mobility Limitation | Eating Behavior
-
Ohio State UniversityCompleted
-
University of PittsburghRobert C. Atkins FoundationCompleted
-
McGill UniversityCompleted
-
Baylor Research InstituteActive, not recruitingHypertension | Risk Reduction Behavior | African Americans | Diet, Carbohydrate-RestrictedUnited States
-
Baylor Research InstituteActive, not recruitingObesity | Weight Loss | Diet Modification | Spinal Cord InjuriesUnited States
-
Tulane UniversityUniversity of Pennsylvania; National Heart, Lung, and Blood Institute (NHLBI); Pennington Biomedical Research CenterRecruitingHyperglycemia | Obesity | PreDiabetes | Gestational Diabetes | Glucose Intolerance During Pregnancy | Lifestyle, HealthyUnited States